MYRIAD GENETICS, INC.

Lobbying for MYRIAD GENETICS, INC.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $250,000.00 expenses · posted Jan 20, 2026

Lobbying activity 1

Medicare/Medicaid

Congressional oversight of Medicare Advantage and prior authorization issues.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem